Meeting
2022 ASCO Annual Meeting
Surufatinib in U.S. patients with soft tissue sarcoma.
Authors
Sujana Movva
Memorial Sloan Kettering Cancer Center, New York, NY
Sujana Movva , Alexander I. Spira , Erika P. Hamilton , Judy S. Wang , Allen Lee Cohn , James F. Strauss , Silvia Stacchiotti , Chris Tucci , John Kauh , Shivani Nanda , Marek K. Kania , Shreyaskumar Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02549937
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11557)
DOI
10.1200/JCO.2022.40.16_suppl.11557
Abstract #
11557
Poster Bd #
461
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
First Author: Arvind Dasari
Poster
2024 ASCO Breakthrough
Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study.
First Author: Ying Cheng
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2023 ASCO Annual Meeting
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
First Author: Saad Zafar Usmani